ClinicalTrials.Veeva

Menu

BAY86-5046 (Betaseron), Non Interventional Studies (BETAEVAL)

Bayer logo

Bayer

Status

Completed

Conditions

Multiple Sclerosis

Treatments

Device: BETACONNECT auto-injector.
Drug: Interferon beta-1b (Betaferon, BAY 86-5046)

Study type

Observational

Funder types

Industry

Identifiers

NCT02121444
BF1414DE (Other Identifier)
17101

Details and patient eligibility

About

This study aims to investigate adherence to therapy among patients treated with Betaferon who are using the BETACONNECT autoinjector.

Enrollment

151 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with the diagnosis of relapsing remitting multiple sclerosis or a clinically isolated syndrome.
  • Patients must be on treatment with Betaferon or the decision to treat patients with Betaferon has been made by the attending physician.
  • Patient and attending physicians must have agreed on the usage of the BETACONNECT auto-injector device
  • Written informed consent must be obtained.

Exclusion criteria

  • Patients receiving any other disease modifying drug.
  • Contraindications of Betaferon described in the Summary of Product Characteristics.

Trial design

151 participants in 1 patient group

Cohort 1
Description:
Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect auto-injector
Treatment:
Device: BETACONNECT auto-injector.
Drug: Interferon beta-1b (Betaferon, BAY 86-5046)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems